Contract Manufacturing Market for live Biotherapeutics and Microbiome Products is estimated to be worth USD 300 million by 2030, growing at a CAGR of 46%, claims Roots Analysis
Manufacturing live biotherapeutic product is both technically challenging and financially demanding; as a result, innovator firms are becoming increasingly reliant on contract service providers to access specialized facilities and optimize overall costs.
Read Detailed Analysis : https://www.rootsanalysis.com/reports/view_document/microbiome-contract-manufacturing/306.html
